MTOR and breast carcinoma: For example, miR-99a, miR-99b, miR-100, miR-199a-3p, miR-224, miR-101-2, miR-544, miR-144-3p, miR-520c and miR-373 have been shown to target mTOR in colorectal cancer, lung cancer, cervical cancer, gastric cancer, breast cancer, hepatocellular carcinoma, salivary adenoid carcinoma, and fibrosarcoma cells [15, 31–39].